OS Therapies announced the submission of Phase 2b clinical and biomarker data for OST-HER2 to the FDA, aiming for accelerated approval of this listeria-based cancer immunotherapy for osteosarcoma in the U.S. by late 2026. The company also plans to seek conditional marketing authorizations in Europe and the U.K. after positive trial results showing significant event-free and overall survival benefits. Upcoming milestones include regulatory meetings in mid-2026 and initiation of a confirmatory Phase 3 trial in Australia. Despite a net loss in 2025 due to R&D and administrative costs, OS Therapies is advancing its pipeline and regulatory strategy to commercialize OST-HER2 globally.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
QuickLogic and PQSecure Technologies demonstrated that PQSecure's CRYSTAL-1000C post-quantum cryptographic IP can be efficiently implemented on QuickLogic's reprogrammable eFPGA fabric within SoCs. This allows field-upgradeable security without costl...
Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
AmpliTech Group marked its fifth anniversary as a public company by ringing the Nasdaq opening bell and announcing record revenue of $25.2 million in fiscal 2025, a 165% increase year-over-year. The company, a US-based leader in RF and microwave sign...
